About Takara Bio
Takara Bio is a publicly listed company based in Frankfurt (Germany) founded in 1925. Developer of gene-based therapies as well as contract services for the industrial and agricultural sector. The company has 1,780 employees. Takara Bio has completed 4 acquisitions, including Clontech, Curio Bioscience and Rubicon Genomics. Its focus areas include Life Sciences, Immunotherapy, Adoptive Cell Therapy and T-Cell. Its legal entity is WaferGen Bio-systems, Inc.
Company details
Takara Bio was founded in 1925 and is headquartered in Frankfurt, Germany. Gene-based therapies are developed by the company, including HF10, an oncolytic herpes simplex virus strain for antitumor activity, MAGE-A4 antigen-specific TCR gene therapy targeting esophageal cancer with retroviral vectors, and MazF-modified T-cells for HIV RNA cleavage. Contract services are also provided to the industrial and agricultural sectors in the biotechnology field.
- Headquarters Frankfurt, Germany
- Employees 1,780
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website takara-bio.com/en/index.html
- Social LinkedIn Facebook
- Legal Name Takara Bio Inc.
- Annual Revenue$301.41 M (USD)3.53as on Mar 31, 2025
- Net Profit$6.96 M (USD)-29.64as on Mar 31, 2025
- EBITDA$45.1 M (USD)-15.95as on Mar 31, 2025
- Employee Count1,780
- Investments & AcquisitionsClontech
& 3 more
People of Takara Bio
20 people are tracked at Takara Bio (1 in leadership, 8 in board & advisors, 11 in team); the tracked headcount is 1,780.
| Name | Role | Group |
|---|---|---|
Koichi Nakao | President & CEO | Leadership |
Masanobu Kimura | Director | Board & advisors |
Tsuyoshi Miyamura | Director | Board & advisors |
Junichi Mineno | Director | Board & advisors |
Yoh Hamaoka | Director | Board & advisors |
Nobuko Kawashima | Director | Board & advisors |
Noriomi Matsumura | Director | Board & advisors |
Kazuko Kimura | Director | Board & advisors |
Mutsumi Kimura | Director | Board & advisors |
Katsuhiko Kusakabe | Senior Executive Officer | Team |
Noritaka Nishiwaki | Operating Officer | Team |
Nobuto Koyama | Operating Officer | Team |
Tatsuji Enoki | Operating Officer | Team |
Akiyuki Sato | Operating Officer | Team |
Kyoko Nakajima | Executive Officer | Team |
Takuya Kakemi | Operating Officer | Team |
Yoshitaka Kimura | Research And Development Manager | Team |
Bakhyt Zhumabayeva | Biotechnology Professinal | Team |
Max Sanchez | Manager Of Field Applications-science And Engineering | Team |
Akira Kodera | Executive Officer | Team |
Complete people profiles for Takara Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Takara Bio
Takara Bio is a publicly listed company on the TSE with ticker symbol 4974 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Dec 2004
- Listed onTSE: 4974
- Listed entityTakara Bio Inc.
- Exchange sectorHealth technology
- ISINJP3460200003
- Share price1,142.00 JPY · 2026-05-11
- Market capitalisation137,514,619,354.00 JPY
- EPS (diluted, trailing year)-59.79 JPY
- Dividend yield1.49%
- Volume (last session)138,600
- Analyst consensusBuy
Financials of Takara Bio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | 45.04B JPY | 1.04B JPY | 6.74B JPY |
| 2023 | 43.51B JPY | 1.48B JPY | 8.02B JPY |
| 2022 | 78.14B JPY | 16.01B JPY | 25.28B JPY |
| 2021 | 67.70B JPY | 19.85B JPY | 33.05B JPY |
| 2020 | 46.09B JPY | 9.55B JPY | 17.74B JPY |
Detailed financial statements for Takara Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Takara Bio
Takara Bio has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Clontech, Curio Bioscience and Rubicon Genomics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Spatial omics solutions are provided for discovery research. | curiobioscience.com | Palo Alto, United States | 2021 | Jan 2025 | •••• | |
Reagents and kits for pre-analytical amplification technologies are supplied. | rubicongenomics.com | Ann Arbor, United States | 2000 | Dec 2016 | $75M | |
Genomic tools are provided for resequencing, genotyping, and expression analysis. | wafergen.com | Fremont, United States | 2002 | May 2016 | $50M | |
Reagents, instruments, and services for life science industries are provided. | clontech.com | Palo Alto, United States | 1984 | Jul 2005 | $60M |
Complete acquisition details for Takara Bio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Takara Bio
6 dated milestones of Takara Bio across 100 years, from founding to its latest funding, stage changes and deals.
- Founded Takara Bio is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Clontech.
- Acquisition Acquires WaferGen.
- Acquisition Acquires Rubicon Genomics.
- Acquisition Acquires Curio Bioscience.
Web traffic of Takara Bio
The website of Takara Bio (takara-bio.com) receives about 4K visits a month.
- Monthly visits4K
▲ 83% vs previous month
Websites whose visitors overlap most with Takara Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
labnext.com | labnext.com | 100% | – | ||
| biocompanion.com | 100% | View details | |||
| illumina.com | 100% | 672.7K | #61,793 | View details | |
anges-mg.com | anges-mg.com | 100% | – | ||
| epigenomics.com | 100% | 2.4K | #6,675,395 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 25 similar websites and full traffic analytics for Takara Bio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 25 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Takara Bio
Complete news archive for Takara Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Takara Bio
Takara Bio was founded in 1925.
Takara Bio is headquartered in Frankfurt, Germany. It is registered at Frankfurt, Hesse, Germany.
Takara Bio has 1,780 employees.
Annual revenue of Takara Bio is $301.41M as on Mar 31, 2025.
Takara Bio was founded in 1925 and is headquartered in Frankfurt, Germany. Gene-based therapies are developed by the company, including HF10, an oncolytic herpes simplex virus strain for antitumor activity, MAGE-A4 antigen-specific TCR gene therapy targeting esophageal cancer with retroviral vectors, and MazF-modified T-cells for HIV RNA cleavage. Contract services are also provided to the industrial and agricultural sectors in the biotechnology field.
Yes, Takara Bio is publicly traded on TSE under the ticker symbol 4974.
Takara Bio has made 4 acquisitions, including Clontech, Curio Bioscience, and Rubicon Genomics.
Takara Bio operates through Wafergen Bio-Systems, Inc..